First-in-human clinical trial to test CAR T cell therapy for pediatric gliomas
The Phase 1 clinical trial is expected to enroll up to 18 children between 4 and 18 years old with pediatric high-grade gliomas.
The Phase 1 clinical trial is expected to enroll up to 18 children between 4 and 18 years old with pediatric high-grade gliomas.
The project will study the impact of race and ethnicity on immunotherapy outcomes in children and adolescent young adult patients with cancer.